We prospectively evaluated a combination of fungal biomarkers in adult haematology patients with focus on their clinical utility at different time points during the course of infection. In total, 135 patients were monitored once to twice weekly for serum (1-3)-ß-d-glucan (BG), galactomannan (GM), bis-methyl-gliotoxin and urinary d-arabinitol/l-arabinitol ratio. In all, 13 cases with proven or probable invasive fungal disease (IFD) were identified. The sensitivity of BG and GM at the time of diagnosis (TOD) was low, but within 2 weeks from the TOD the sensitivity of BG was 92%. BG >800 pg/mL was highly specific for IFD. At a pre-test probability of 12%, both BG and GM had negative predictive values (NPV) >0.9 but low positive predictive values (PPV). In a subgroup analysis of patients with clinically suspected IFD (pre-test probability of 35%), the NPV was lower, but the PPV for BG was 0.86 at cut-off 160 pg/ mL. Among IFD patients, 91% had patterns of consecutively positive and increasing BG levels. Bis-methyl-gliotoxin was undetectable in 15 patients with proven, probable and possible IA. To conclude, BG was the superior fungal marker for IFD diagnosis. Quantification above the limit of detection and graphical evaluation of the pattern of dynamics are warranted in the interpretation of BG results.
attributable to IFD is high, 1, 10, 11 and early diagnosis remains a challenge to clinicians. blood sampling in relation to onset of disease. [21] [22] [23] [24] [25] Furthermore, the clinical use of GM and BG has been partly limited by false-positive results, an issue that has been addressed in numerous studies. We recently reported that patients treated with the chemotherapeutic drug pegylated asparaginase had a high frequency of false-positive BG, presumably due to high triglyceride levels in serum.
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Gliotoxin, a metabolite produced by Aspergillus spp. during invasive growth, 27, 28 has been detected in sera of patients with IA and proposed as a possible marker of IA. 29, 30 Bis(methyl)gliotoxin (bm-gliotoxin), the inactive metabolite of gliotoxin, was later on presented as a more stable and reliable marker for IA. 31 Methods for detection of bm-gliotoxin in serum using high-performance thin-layer chromatography with ultra-violet or mass spectrometric detection have been developed and proposed as a diagnostic tool for IA. d-arabinitol (DA), a metabolite of Candida spp. with the exception of C. krusei and C. glabrata, can be detected in serum and urine by gas chromatography and mass spectrometry in patients with invasive candidiasis. [32] [33] [34] A method developed to correct for endogenously produced arabinitol by calculating the ratio of DA and L-arabinitol in urine (DA/LA ratio) has been proposed as a useful marker to aid the diagnosis of invasive candidiasis in haematology patients. 35, 36 Large efforts have been devoted to evaluate the diagnostic performance of BG and GM in haematology patients at risk of IFD, but there is still no consensus on how to use these markers in clinical practice. The diagnostic utility of urinary DA/LA ratio and bm-gliotoxin has been less investigated. The primary aim of this study was to prospectively evaluate the diagnostic performance of a combination of fungal biomarkers (ie BG, GM, bm-gliotoxin and DA/LA-ratio) in adult patients with haematological malignancies at high risk of developing IFD, with emphasis on describing their clinical utility for diagnosis at different time points during the course of infection. 
| PATIENTS AND ME THODS

| Analysis of fungal biomarkers
The Glucatell ® assay kit (Ass. Cape Cod, MA, USA) was used for measuring serum levels of BG. The sera were pretreated and analysed in duplicate according to the manufacturer's instructions.
Fresh serum samples from the Gothenburg cohort were analysed consecutively, and serum aliquots initially frozen at −80°C from the Lund cohort were analysed retrospectively for BG. The test results were initially reported as numerical values up to the highest level of detection (400 pg/mL). Subsequently, aliquots from frozen serum samples yielding BG >400 pg/mL were titrated to obtain an exact value for BG.
Galactomannan levels in serum were measured using the Platelia™ Aspergillus Enzyme Immunoassay (Bio-Rad, Marnes-laCoqette, France) according to the manufacturer's instructions. GM was analysed retrospectively from serum aliquots initially frozen at −80°C.
Bis(methyl)gliotoxin in serum was analysed retrospectively from serum aliquots initially frozen at −80°C. Maximum storage time before analysis was 2 years. High-performance liquid chromatography tandem mass spectrometry (HPLC MS/MS) was used. For detailed information, see Appendix S1.
Urine samples were initially administered to a filter paper, left to evaporate and stored at room temperature for future analyses of DA/LA ratio. The samples were subsequently extracted from the filter papers, and DA/LA ratios were then analysed with gas chromatography mass spectrometry (GC-MS). for any potential delay in diagnosis. For the patients that were not classified as IFD during the study period, the serum sample with the maximum value of the fungal biomarker among all samples collected during the study period was used in the analyses.
| Statistical analyses
Descriptive statistics are presented as median values with interquartile ranges. Sensitivity and specificity were calculated using For (1-3)-ß-d-glucan and galactomannan, the number of analysed samples represents the samples included in the assessment of diagnostic performance, that is, for patients with IFD or invasive aspergillosis (IA), samples collected during the period of 2 wk before and after the time of diagnosis; for patients with no IFD, samples collected during the entire study period. allo-HSCT, allogeneic haematopoietic stem cell transplantation; IFD, invasive fungal disease. a Myelofibrosis (n = 3), haemophagocytic lymphohistiocytosis (n = 1), multiple myeloma (n = 2), polycytemia vera (n = 1). b Proven (n = 4), probable (n = 9) and possible (n = 10) IFD according to EORTC/MSG criteria. In all, 17 of these were proven (n = 2), probable (n = 5) or possible (n = 10) invasive aspergillosis.
two-by-two tables with 95% confidence interval (CI). Due to the not completely consecutive inclusion of study patients, the predictive values of fungal biomarkers was evaluated using Bayes'
formula at an expected IFD prevalence, or pre-test probability, of 12%, consistent with the prevalence of IFD found in other studies. 10, 26, 38 Due to small sample sizes and/or skewness of data, the One patient with probable IA had mould-active prophylaxis and thus a break through infection (patient no. 7). There was no significant difference in the proportion of patients with mould-active prophylaxis among patients with IA and patients with no IFD (6% and 10%, respectively, P > .9).
| RE SULTS
| Patients and IFD cases
| Diagnostic performance of fungal biomarkers
In all, 97 serum samples from 25 study patients with clinically suspected IFD according to the clinician's judgement were analysed for bm-gliotoxin. Out of these, 15 patients had proven (n = 1), probable (n = 4) or possible (n = 10) IA; two had proven Fusarium and Candida infection, respectively; and eight patients had no IFD. All samples were negative for bm-gliotoxin. Thus, we decided not to pursue further analyses. Unfortunately, two patients with proven and probable IA were not analysed for bm-gliotoxin due to lack of serum.
A total of 1801 urine samples from 130 study patients were analysed for DA/LA ratio. The DA/LA ratio was negative (<3), indeterminate (3-5) and positive (>5) in 80%, 17% and 3% of all urine samples, respectively. Since there was only one case of blood culture-verified invasive candidiasis, a case of C. krusei known not to produce darabinitol, 33 the results of the urinary DA/LA ratio were not further evaluated.
The diagnostic performance of BG and GM for the diagnosis of overall IFD and IA, respectively, at different time points during the course of infection is shown in Table 3 . Both BG and GM had a low sensitivity early during the course of infection (at TOD), even at the lowest cut-off levels (69% and 33%, respectively). The sensitivity of BG was considerably higher (92%) when sampling was performed later during the course of infection. For GM, the sensitivity was low (43%) also later during the course of infection.
The specificity of BG at a cut-off level of 80 pg/mL was only 41%
when using one positive sample, but 80% when using 2 consecutive positive samples to define a positive test result. At a cut-off level of 800 pg/mL, the specificity was 100%. The specificity of GM was >90% at cut-off levels 0.5 and 1.0. Combining BG and GM (ie with the requisite of both being positive for a positive test result) at any cut-off level increased specificity but gave a very low sensitivity.
Two patients with proven or probable IA had a mould-active drug at the TOD (as empiric treatment and prophylaxis, respectively), and one patient with probable IA was started on mould-active treatment after, but within 2 weeks from TOD. All three developed positive BG levels but only two had detectable GM. In addition, three patients with proven candidiasis, proven Fusarium infection and PJP, respectively, were started on antifungal treatment after, but within 2 weeks from TOD; all of them developed positive BG levels. Due to the small sample size, statistical analysis with stratification for antifungal treatment was not allowed.
The predictive values and likelihood ratios of BG and GM upon screening for IFD or IA at an expected pre-test probability of 12% are shown in Table 4 . Both markers showed a high NPV (>0.9) at the lower cut-off levels, but a low PPV at all cut- (Table S1 ).
In all, 48 serum samples, from 21 patients, with a BG value of >400 pg/mL in the primary analysis, were titrated and reanalysed to obtain an exact BG value (Figure 1 ). The median BG-level in patients with proven and probable IFD was significantly higher than in patients without IFD (P < .0001). In total, 80% of the titrated samples from patients with IFD were higher than 800 pg/mL, whereas none of the samples from patients without IFD exceeded 800 pg/mL. An evaluation of the impact of elevated triglyceride levels on BG levels in serum (based on analysis of BG samples collected from patients without IFD with triglyceride analyses performed on the same day as BG sampling) was done. As shown in Figure 2 , serum triglyceride levels strongly correlated with BG levels among patients without IFD (r = .7, P < .0001).
TA B L E 2
Sequential BG serum levels in individual patients were evaluated graphically to determine the pattern of BG dynamics and its relation to IFD. Samples were considered sequential if collected with a maximum interval of 7 days. For the patients with IFD, the serum samples drawn within 2 weeks before and after the TOD were included in this evaluation. Seven patients without IFD and one patient with probable PJP did not have sequential BG samples and were excluded from this analysis. As shown in Table 5 
| The impact of radiology assessment on fulfilment of EORTC criteria
CT scans from 32 patients with pathological findings according to local radiologist were additionally reviewed by a chest radiologist specialised in fungal infections and this assessment was subsequently employed for the classification of IFD in this study. We also wanted to determine whether the radiological assessment by less specialised Value of the fungal marker at the TOD. The TOD represents the best estimate of the true time of diagnosis within a time frame of 2 wk prior to the date the patient first fulfilled EORTC criteria leading to an IFD classification. b Maximum value of the fungal marker within 2 wk from the TOD. c Based on the maximum value of the fungal marker during the entire sampling period. d Defined by two positive test results within 1 wk above the specified cut-off level. e IFD n = 11 (one patient with IA and one patient with PJP had no samples available for titration of BG). f IA n = 6 (one patient with IA did not have analysed GM at the TOD).
TA B L E 3 Diagnostic performance of BG and GM for the diagnosis of IFD at different time points during the course of infection specialised radiologist mentioned the same term in 7 patients. The IFD classification according to EORTC criteria based on reports from local and specialised radiologists had different outcome for 7 of the 32 patients (22%).
| D ISCUSS I ON
Given the complexity of the clinical picture of IFD, there is a need The calculations are based on the value of the fungal marker at the time of diagnosis (TOD) in 13 patients with probable or proven IFD (for BG) and 6 patients with probable or proven IA (for GM), and on the maximum value of the fungal marker during the entire sampling period in 112 patients with no IFD. In all, 10 patients with possible IFD were excluded. Calculations of predictive values are based on an expected pre-test probability (ie IFD prevalence) of 12%. BG, (1-3)-ß-D-Glucan GM, galactomannan; IFD, invasive fungal disease; NLR, negative likelihood ratio; NPV, negative predictive value; ODI, optical density index; PLR, positive likelihood ratio; PPV, positive predictive value.
F I G U R E 1 Dilution of samples with (1-3)-ß-D-Glucan (BG) >400 pg/mL. In total, 48 serum samples yielding a BG value >400 pg/mL in the primary analysis were titrated to obtain an exact BG value. This figure shows the results of all diluted BG samples with respect to invasive fungal disease (IFD) classification. Vertical lines represent the median and error bars represent the interquartile range. The BG sample marked as an * yielded a value of >20 000 pg/mL after dilution and reanalysis and corresponds to patient no. 3 with proven, therapy-resistant invasive aspergillosis. The groups proven/probable IFD and no IFD were compared using the Mann-Whitney test an animal model of invasive aspergillosis. In addition, quantification of BG above the maximum limit of detection seems to give valuable information given that the specificity at a cut-off level of 800 pg/ mL was 100% in this study. In contrast to our results, older studies report that positive GM precedes other clinical signs of aspergillosis suggesting a capacity for early diagnosis of IA. [40] [41] [42] In our study, the sensitivity of GM was very low at TOD and did not exceed 57% at any time point in the course of infection. However, the fact that two of these patients were on mould-active drugs at TOD may have affected the sensitivity negatively.
43
Our results showed a high NPV (>0.9), but a very low PPV for both BG and GM when used as screening markers for IFD at an expected 12% pre-test probability of IFD (which mirrors the prevalence of IFD in other studies 10, 26, 38 
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